Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting the genomic science, reimbursement discussions, and clinical-trial data buried inside GeneDx’s SEC disclosures can feel like decoding DNA itself. From recognizing revenue tied to whole-genome tests to tracking how rapid NICU sequencing affects margins, the company’s reports are dense with technical language. That’s why investors searching for “GeneDx SEC filings explained simply” start here.
Stock Titan’s platform turns those complexities into clarity. Our AI reads every 10-K annual report, 10-Q quarterly earnings report, and 8-K material events the moment they hit EDGAR, then serves up concise highlights. Need the “GeneDx annual report 10-K simplified” to see year-over-year R&D spending? Done. Curious about clinical-trial milestones disclosed in an 8-K? They’re distilled in seconds—“GeneDx 8-K material events explained.” Real-time alerts flag each “GeneDx Form 4 insider transactions real-time,” letting you monitor “GeneDx executive stock transactions Form 4” without combing filings. Our summaries also connect reimbursement risk factors to revenue trends, so “GeneDx earnings report filing analysis” becomes a quick read instead of a weekend project.
Every filing type unlocks a different lens on this precision-medicine pioneer: the “GeneDx quarterly earnings report 10-Q filing” reveals test-volume growth; the “GeneDx proxy statement executive compensation” shows how leadership is incentivized to expand the rare-disease dataset; “GeneDx insider trading Form 4 transactions” expose buying or selling before pivotal FDA updates. With AI-powered summaries, expert context, and real-time coverage of all forms, understanding GeneDx’s path—from lab bench to bedside—is finally straightforward. Investors use these insights to spot emerging reimbursement trends, evaluate cash burn, and benchmark genomic-data assets—all without wading through hundreds of pages. For anyone “understanding GeneDx SEC documents with AI,” this is the single page to bookmark.
Thomas Fuchs, a director of GeneDx Holdings Corp. (ticker shown as WGS), was granted 3,438 restricted stock units (RSUs) on 09/17/2025. Each RSU converts into one share of Class A Common Stock for no consideration when settled. The award vests in three equal installments on 09/17/2026, 09/17/2027, and 09/17/2028, subject to the reporting persons continued service. Following the grant, the reporting person beneficially owns 3,438 shares of Class A Common Stock as a direct owner. The Form 4 was signed by an attorney-in-fact on 09/19/2025.
Thomas Fuchs filed an initial Form 3 reporting his relationship to GeneDx Holdings Corp. (ticker: WGS) as a Director. The event date triggering the filing is 09/17/2025. The form states that no securities are beneficially owned by the reporting person. The filing is signed on behalf of Mr. Fuchs by Bridget Brown, Attorney-in-Fact dated 09/19/2025.
Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. amended a Form 4 to correct a typographical error and to report the vesting and acquisition of restricted stock units. The amendment clarifies that on 09/16/2025 Mr. Feeley acquired 7,197 restricted stock units, each convertible into one share of Class A common stock for no consideration, increasing his beneficial ownership to 12,483 shares.
The filing notes the original Form 4 filed on 09/18/2025 incorrectly showed a disposition code where an acquisition code was intended; no other line items were changed. The amendment is signed by an attorney-in-fact on behalf of the reporting person.
GeneDx Holdings Corp. (WGS) Form 4 shows Chief Financial Officer Kevin Feeley reported transactions on 09/16/2025 related to the vesting and settlement of restricted stock units (RSUs). 7,197 RSUs were treated as vested and settled for no cash consideration, and the Reporting Person triggered a sell-to-cover transaction that sold 3,728 shares at a weighted average price of $121.4727 to satisfy tax withholding. After these transactions, Mr. Feeley directly beneficially owned 8,755 shares of Class A common stock.
In addition to direct holdings, the filing discloses contingent rights to receive 124,633 RSU shares and options to purchase 27,152 shares, which vest over time per their terms. The sale is described as non-discretionary and solely to cover withholding obligations.
Insider transactions reported for GeneDx Holdings Corp. (WGS) show Katherine Stueland received 18,750 restricted stock units (RSUs) on 09/16/2025 that convert to Class A common stock for no cash consideration upon settlement, and sold 10,501 shares of Class A common stock the same day at a weighted-average price of $121.4727 per share as part of a block trade. The sale was disclosed as a "sell to cover" transaction to satisfy tax withholding tied to the RSU vesting and was not discretionary. After these transactions the reporting person directly beneficially owned 14,578 shares of Class A common stock and, separately, beneficially owned RSUs representing up to 444,539 shares and options for 107,610 shares, subject to their vesting terms.
Katherine Stueland, Chief Executive Officer and Director of GeneDx Holdings Corp. (WGS), reported transactions on 09/09/2025 showing settlement of 6,546 RSUs for no consideration and contemporaneous sales to cover tax withholding. The Form 4 shows two sales: 3,639 shares at $128.05 and 18 shares at $129.079, leaving the reporting person with 6,329 shares of Class A common stock beneficially owned.
In addition to those shares, the filing discloses contingent rights to 463,289 RSUs and options to purchase 107,610 shares, which vest per their terms. The RSUs vested at 6.25% quarterly starting March 9, 2023. The report was signed by attorney-in-fact on 09/11/2025.
GeneDx Holdings Corp. (WGS) insider filing shows CFO Kevin Feeley reported the vesting and settlement of 2,462 RSUs on 09/09/2025, which represent contingent rights to Class A common stock settled for $0 per share. To satisfy tax withholding on the settlement, the reporting person executed two sell transactions that disposed of 1,266 shares at $128.05 and 6 shares at $129.09. After these transactions Mr. Feeley beneficially owned 5,286 shares of Class A common stock directly, plus RSUs representing up to 131,830 shares and options covering 27,152 shares that vest per their terms.
GeneDx Holdings Corp. (WGS) Form 4 summary: The company's Chief Financial Officer received 717 restricted stock units (RSUs) that settled as Class A common stock and immediately caused a tax-withholding sale. A total of 378 shares were sold in a "sell-to-cover" transaction at a weighted-average price of $125.8096 per share to satisfy withholding obligations. After the transactions, the reporting person directly beneficially owned 4,096 shares of Class A common stock and retained RSUs and stock options representing potential future ownership of 134,292 RSU shares and 27,152 option shares, which vest per their terms. The disclosed RSU settlement indicates an ongoing compensation vesting schedule that vests 6.25% quarterly over four years from December 1, 2022.
Ryan Jason, a director of GeneDx Holdings Corp. (WGS), reported multiple open-market dispositions of Class A common stock on 08/27/2025. The Form 4 records seven separate sales totaling 39,222 shares (8,818; 8,969; 5,443; 3,452; 9,890; 1,500; 1,150) at weighted-average prices ranging roughly from $124.50 to $130.19 per share. After these transactions, the filing shows beneficial ownership positions reported as indirect through the "Jason Ryan 2024 GRAT," with the largest reported post-transaction position at 132,538 shares and the smallest at 11,904 shares; one line shows 103,284 shares directly or indirectly owned. The filing discloses that Jason Ryan is trustee and sole annuitant of the GRAT and remains the beneficial owner of securities held by the trust.
FAQ
What is the current stock price of GeneDx Holdings (WGS)?
What is the market cap of GeneDx Holdings (WGS)?
